The German Breast Group (GBG) is the leading breast cancer study group in Germany, conducting clinical trials in the adjuvant, neoadjuvant, preventative and palliative settings. One focus of the GBG is neoadjuvant studies, which have a long and successful history in Germany. The aim of neoadjuvant studies is to improve operability and to gain more information about the tumour itself in terms of the chemotherapy (in vivo) as well as regarding the biology in general. However, preventative, palliative and adjuvant studies are also important components of the GBG. This article is an overview of the structure and working practice of the GBG and gives a sample of trials currently being led by the GBG.
The German Breast Group (GBG) is a leading study group covering the to discuss the progress of the study and to be able to react quickly in case of safety concerns or in case of new findings that need to be implemented in the study design.
A network of more than 650 national and international centres participates in these trials. In 2008 more than 4,250 patients were enrolled into GBG studies, which is about 8.5% of all newly diagnosed breast cancer patients in Germany. Overall, about 11% of all primary breast cancer patients receive their (neo)adjuvant therapy within a clinical trial. 
Neoadjuvant Studies
The focus of the GBG is the neoadjuvant field, which has a long history in Germany. Since the first studies in the mid-1990s this has been a story of success. The reason neoadjuvant studies in breast cancer are particularly popular and successful probably lies in the way breast cancer is treated in Germany. Diagnostic, systemic and surgical treatment lies in general in the hands of the gynaecologist, who co-operates in a multidisciplinary team. Therefore, there is a single point of contact for the patients, which reduces time.
Innovative strategies, especially the neoadjuvant concept, could be implemented into daily practice via a tight clinical trial network. The advantages of such treatment designs are increased rates of breastconserving therapy, in vivo testing of chemosensitivity, and therefore prediction of the patient's prognosis, and gaining more information about the tumour biology with translational research projects.
The GEPARDO study, the first neoadjuvant GBG trial, was published in 2001 in the Journal of Clinical Oncology. 1 The study was designed to investigate the possibility of the combination of doxorubicin and docetaxel ± tamoxifen (ADOC ± Tam) regardless of hormone receptor status, assuming that tamoxifen would overcome resistance to chemosensitivity. This regimen was further investigated in a series of Breast Cancer The subsequent GeparTrio The safety analysis demonstrated that this approach was feasible without increasing the cardiac side effects, but with an almost doubled pathological complete response rate. 7 Therefore, the GeparQuinto trial (goal n=2,500 patients), which is currently recruiting, is evaluating in a head-to-head comparison whether trastuzumab or lapatinib as anti-Her2 agent in the neoadjuvant setting should be favoured. Her2-negative patients are randomised to 4xEC followed by four x docetaxel with or without bevacizumab. After completing the first four cycles of EC, a response evaluation by ultrasound will separate the responding from the non-responding group.
The latter will stop bevacizumab and be randomised to paclitaxel weekly with or without the mTor inhibitor RAD001 (everolimus). The responder group will continue according to the initial randomisation with or without bevacizumab and continue chemotherapy with docetaxel (EC-DOC ± bevacizumab). The rate of pathological complete response, defined as no invasive tumour in the breast and axillary lymph nodes (ypT0/Tis; ypN0), is the primary end-point in this trial.
In 2002 the AGO started its first neoadjuvant trial (AGO 1 study), elaborating the dose-dense approach in the neoadjuvant setting. It was demonstrated that the dose-dense treatment (ddE-ddP) followed postoperatively by cyclophosphamide/methotrexate/5-fluorouracil (CMF) is superior not only in terms of improved pCR rates but also in terms of improved long-term outcome. 8 The PReoperative Epirubicin Paclitaxel ARanEsp (PREPARE) trial, which started thereafter, also demonstrated a superior pCR rate for the dose-dense approach (ddE-ddP-CMF) compared with standard EC-P. In parallel, the Taxol Epirubicin
Cyclophosphamid Herceptin NeOadjuvant (TECHNO) trial evaluated the addition of trastuzumab to standard EC-P, starting with trastuzumab after completing the treatment including antracycline. The GBG entered into the conduct of these two trials at a later time-point.
All eight trials (five by the GBG and three by the AGO) have been incorporated into one database. The first preliminary results of more than 6,000 patients treated with an antracycline-and taxanecontaining chemotherapy in the neoadjuvant setting were presented at last year's San Antonio Breast Cancer Symposium (SABCS). 9 The two groups have joined forces: the GeparQuinto and the GeparQuattro study are both intergroup trials of the GBG and the AGO, enabling better recruitment and a more sophisticated translational programme. More details are provided in Table 1 .
Another neoadjuvant study of the GBG is the SOFIA study, with a primary focus on translational outcome. The study investigates the small molecule sorafenib -which acts via inhibition of the Raf/Ras kinases as well as neoangiogenesis -in combination with EC-P weekly. 10 
Adjuvant Studies
To further improve adjuvant treatment of early node-positive breast cancer is a permanent goal. A modern and biologically highly The German Breast Group -Healing Through Innovation, Competence and Partnership
interesting concept to achieve this is the dose-dense, dose- The GBG has also been undertaking adjuvant research in elderly patients. As the elderly patient is often under-represented in clinical trials but represents a great proportion of affected patients, more data need to be collected regarding safety and efficacy in this population. In the ICE I study, capecitabine ± ibandronate in the elderly was under investigation. It was shown to be very well tolerated and seemed feasible in this population. The study has just been closed and the first efficacy data are eagerly awaited in 2010.
In a meta-analysis the effect of taxanes on elderly patients was evaluated. The study was a joint project together with the AGO, the Westdeutsche Studiengruppe (WSG) and the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). The ICE II study, which has just begun recruiting, investigates the combination of nab-paclitaxel with capecitabine versus EC or CMF in patients with high-risk primary breast cancer in the elderly either according to a clinicopathological algorithm or by measuring uPA/PAI 1.
Palliative Studies
In the future the GBG wants to further distinguish between high-and low-risk patients with metastasised breast cancer in order to treat patients according to their disease, thus avoiding overtreatment in a situation where maintaining the patient's quality of life is essential. Therefore, studies were designed taking this into account. Breast Cancer
The RADAR study offers a promising approach for low-risk patients The TaBeA study is one example for women in the high-risk metastasised situation, and aims to establish a three-drug regimen including two cytotoxic agents and one molecularly targeted drug. It is a randomised phase III study to determine the efficacy of a taxane and bevacizumab with or without capecitabine 1,800mg/m 2 as firstline chemotherapy. As the primary objective is PFS, taxanes are given in combination with bevacizumab until progression or unacceptable toxicity occurs.
Taxanes and capecitabine are all highly active single agents for the treatment of breast cancer and show an acceptable toxicity profile.
The addition of the VEGF inhibitor bevacizumab to these cytotoxic agents showed improved response rates for the combination with capecitabine and improved PFS rates for the combination with paclitaxel as well as docetaxel. A combination of all three drugs is therefore considered to be a promising regimen in these high-risk situations of metastatic breast cancer. This trial is again being conducted together with the AGO.
Translational Research
The GBG has also focused on translational research as a prerequisite for all trials. Neoadjuvant studies are optimal for the incorporation of 
